Huisheng Biotech (300871.SZ), a veterinary drug manufacturer listed on the SZSE, reported a strong performance in its 2026 interim results despite challenges in China’s livestock sector. The company achieved a net profit of 206 million yuan (approximately $30.6 million), a 75.59% increase from the previous year, with total revenue rising 5.20% to 865 million yuan (approximately $128.3 million). The growth was fueled by a 13.56% rise in its veterinary API segment and a remarkable 72.79% increase in overseas sales, compensating for a decline in domestic formulation sales.
The company also significantly increased its R&D spending by over 70% to enhance long-term competitiveness and maintain a focus on technological innovation and integration between APIs and formulations. Despite the positive results, concerns remain regarding the recovery of the domestic livestock sector and the sustainability of overseas market growth. Overall, Huisheng Biotech’s strategic shift towards international markets and cost optimization initiatives appear to be paying off, reducing vulnerability to local market fluctuations.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.biggo.com/news/60b9e8c0-bcc1-465c-9779-e60f1020f750
